The manufacturers announce that Zemcelpro® (dorocubicel), also referred to as UM171 cell therapy, has obtained conditional marketing authorization in Europe from the European Commission. Following that approval, the company reports that it has entered into exclusive licensing and supply agreements with Medexus for the Canadian market. The announcement states that Medexus receives the rights covered by these agreements, including licensing and supply arrangements related to Zemcelpro/UM171.
Across the sources provided, the key points are that the therapy is already approved under conditional terms in Europe and that similar commercial arrangements for Canada are being established through Medexus. The releases frame the deals as part of the commercialization and distribution process for Canada, but they do not specify pricing, patient access timelines, or clinical performance details beyond the fact of the conditional European authorization.
